Announced just before the turn of the year, the European Seventh Framework Programme allocated â¬2.9 million to TiGenix and Cellerix to drive forward the development of Cx611 to treat rheumatoid arthritis.
As part of the REGENER-AR consortium which received a total of â¬5.9 million funding, TiGenix CEO Eduardo Bravo commentated by saying, "we look forward to collaborating with our partners, all of whom are dedicated to advancing cell therapy to the clinic." See full article here.
Eduardo Bravo will be an integral member of the elite speaker faculty at the World Stem Cell & Regenerative Medicine Congress 2012.
Under the title, "Progressing into phase III with an orphan indication" the CEO of TiGenix will be sharing his experiences and the crucial lessons learned during late stage clinical development in the pursuit of market approval.
To have unique access to Eduardo's insight and more, register here . Make sure you do so before the 27th January and take advantage of our first and lowest early bird price.